Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
familial amyloidosis
patisiran
polyneuropathy
tafamidis
transthyretin
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
revised:
17
05
2024
received:
11
01
2024
accepted:
29
05
2024
medline:
11
7
2024
pubmed:
11
7
2024
entrez:
11
7
2024
Statut:
aheadofprint
Résumé
Hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN [v for variant]) is a rare, progressive disease associated with multisystemic impairments. This study assessed the real-world outcomes of patients with ATTRv-PN who switched from tafamidis to patisiran, as well as the reasons for the treatment switch. This was a retrospective chart review study at a large expert referral center. Data were extracted from medical charts of patients with ATTRv-PN who switched from tafamidis to patisiran on or before 30 August 2019. Data elements included demographic and clinical characteristics, rationale for switch, and disease measures evaluated from tafamidis initiation through the 12-month patisiran treatment period. Among the 24 patients with ATTRv-PN included in the study, 50.0% had a V30M variant, and the mean (SD) age was 67.3 (8.0) years. During tafamidis treatment (mean [SD] = 30.1 [17.5] months) before switching to patisiran, patients worsened across multiple polyneuropathy measures, including walking ability, Neuropathy Impairment Score, and autonomic function. Neuropathic disease progression on tafamidis was the principal reason for switching to patisiran. After 12 months on patisiran (mean [SD] = 11.7 [1.4] months), patients experienced attenuated disease progression or improvement in the aforementioned measures of polyneuropathy. Switching from tafamidis to patisiran attenuated the rate of functional decline, and most patients experienced stabilization or improvement of at least one polyneuropathy measure within 12 months of patisiran treatment. Timely switch from tafamidis to patisiran can be beneficial to avoid rapid disease progression in patients with ATTRv-PN.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN [v for variant]) is a rare, progressive disease associated with multisystemic impairments. This study assessed the real-world outcomes of patients with ATTRv-PN who switched from tafamidis to patisiran, as well as the reasons for the treatment switch.
METHODS
METHODS
This was a retrospective chart review study at a large expert referral center. Data were extracted from medical charts of patients with ATTRv-PN who switched from tafamidis to patisiran on or before 30 August 2019. Data elements included demographic and clinical characteristics, rationale for switch, and disease measures evaluated from tafamidis initiation through the 12-month patisiran treatment period.
RESULTS
RESULTS
Among the 24 patients with ATTRv-PN included in the study, 50.0% had a V30M variant, and the mean (SD) age was 67.3 (8.0) years. During tafamidis treatment (mean [SD] = 30.1 [17.5] months) before switching to patisiran, patients worsened across multiple polyneuropathy measures, including walking ability, Neuropathy Impairment Score, and autonomic function. Neuropathic disease progression on tafamidis was the principal reason for switching to patisiran. After 12 months on patisiran (mean [SD] = 11.7 [1.4] months), patients experienced attenuated disease progression or improvement in the aforementioned measures of polyneuropathy.
CONCLUSIONS
CONCLUSIONS
Switching from tafamidis to patisiran attenuated the rate of functional decline, and most patients experienced stabilization or improvement of at least one polyneuropathy measure within 12 months of patisiran treatment. Timely switch from tafamidis to patisiran can be beneficial to avoid rapid disease progression in patients with ATTRv-PN.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16384Subventions
Organisme : Alnylam Pharmaceuticals
Informations de copyright
© 2024 Analysis Group, Alnylam Pharmaceuticals and The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387‐404.
Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107‐S112.
Vita G, Vita GL, Stancanelli C, Gentile L, Russo M, Mazzeo A. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurol Sci. 2019;40(4):661‐669.
Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin‐related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8(1):31.
Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti‐Pellié C, Planté‐Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008;15(3):181‐186.
Adams D, Sekijima Y, Conceição I, et al. Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment. Lancet Neurol. 2023;22(11):1061‐1074.
Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85(8):675‐682.
Inês M, Coelho T, Conceição I, Ferreira L, de CM, Costa J. Health‐related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study. Orphanet J Rare Dis. 2020;15(1):67.
Gertz MA, Kyle RA, Thibodeau SN. Familial amyloidosis: a study of 52 North American‐born patients examined during a 30‐year period. Mayo Clin Proc. 1992;67(5):428‐440.
Coelho T, Maia LF, da Martins SA, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785‐792.
Said G, Grippon S, Kirkpatrick P. Tafamidis. Nat Rev Drug Discov. 2012;11(3):185‐186.
Planté‐Bordeneuve V, Gorram F, Salhi H, et al. Long‐term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol. 2017;264(2):268‐276.
Ungerer MN, Hund E, Purrucker JC, et al. Real‐world outcomes in non‐endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20‐year German single‐referral centre experience. Amyloid. 2021;28(2):91‐99.
Lamb YN, Deeks ED. Tafamidis: a review in transthyretin amyloidosis with polyneuropathy. Drugs. 2019;79(8):863‐874.
Zhao Y, Xin Y, Song Z, He Z, Hu W. Tafamidis, a noninvasive therapy for delaying transthyretin familial amyloid polyneuropathy: systematic review and meta‐analysis. J Clin Neurol. 2019;15(1):108‐115.
Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ. Influence of baseline neurologic severity on disease progression and the associated disease‐modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis. 2018;13(1):225.
Barroso FA, Judge DP, Ebede B, et al. Long‐term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24(3):194‐204.
Cortese A, Vita G, Luigetti M, et al. Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non‐endemic area. J Neurol. 2016;263(5):916‐924.
Monteiro C, Mesgazardeh JS, Anselmo J, et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019;4(12):e126526.
Adams D, Suhr OB, Dyck PJ, et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol. 2017;17(1):181.
Adams D, Gonzalez‐Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11‐21.
Adams D, Polydefkis M, González‐Duarte A, et al. Long‐term safety and efficacy of patisiran for hereditary transthyretin‐mediated amyloidosis with polyneuropathy: 12‐month results of an open‐label extension study. Lancet Neurol. 2021;20(1):49‐59.
Hollis L, Madeline M, Cecilia H, Jing LM. Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin‐mediated amyloidosis. Neurodegen Dis Manag. 2020;10(5):289‐300.
Coelho T, Waddington CM, Chao C‐C, et al. Characteristics of patients with hereditary transthyretin amyloidosis‐polyneuropathy (ATTRv‐PN) in NEURO‐TTRansform, an open‐label phase 3 study of eplontersen. Neurol Ther. 2022;12:267‐287.
Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143‐155.
Yarlas A, Gertz MA, Dasgupta NR, et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019;60(2):169‐175.
González‐Duarte A, Berk JL, Quan D, et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin‐mediated amyloidosis. J Neurol. 2020;267(3):703‐712.
Agarwal S, Bither C, Fajardo J, et al. Patient perspective on hereditary transthyretin‐mediated (hATTR) amyloidosis: a qualitative review. Heart Lung. 2020;49(2):213.
Karam C, Dimitrova D, Christ M, Heitner SB. Carpal tunnel syndrome and associated symptoms as first manifestation of hATTR amyloidosis. Neurol Clin Pract. 2019;9(4):309‐313.
Obici L, Suhr OB. Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clin Auton Res. 2019;29(Suppl 1):55‐63.
Luigetti M, Romano A, Di PA, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109‐123.
Denier C, Ducot B, Husson H, et al. A brief compound test for assessment of autonomic and sensory‐motor dysfunction in familial amyloid polyneuropathy. J Neurol. 2007;254(12):1684‐1688.
Lin X, Yarlas A, Vera‐Llonch M, et al. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta‐analysis. BMC Neurol. 2021;21(1):70.
Wixner J, Ueda M, Marques JW, et al. OP044: Patisiran global open‐label extension study at 36 months: effect of long‐term treatment on mortality and ambulatory function in patients with hATTR amyloidosis with polyneuropathy.
United States Food and Drug Administration. Highlights of prescribing information: AMVUTTRA (vutrisiran). 2022. Accessed November 30, 2022, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215515s000lbl.pdf
Keam SJ. Vutrisiran: first approval. Drugs. 2022;82(13):1419‐1425.
Commission de la transparence. Avis. 2019;inotersen 1‐23. Accessed June 29, 2023. https://www.has‐sante.fr/upload/docs/application/pdf/2019‐04/tegsedi_pic_ins_avis3_ct17282.pdf
Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2022;1–9:18‐26.
Polydefkis MJ, Pareyson D, Adams DD, et al. Comparison of eficacy outcomes with vutrisiran vs. patisiran in hATTR amyloidosis with polyneuropathy: post‐hoc analysis of the HELIOS‐A Study.
González‐Duarte A, Adams D, Tournev IL, et al. HELIOS‐A: results from the Phase 3 study of vutrisiran in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy.